F. Shepherd

Publications887
h-index112
Citations55,482
Highly Influential Citations2,183
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • M. Tsao
  • 383 Publications • 18,789 Citations
  • N. Leighl
  • 486 Publications • 11,991 Citations
  • P. Jänne
  • 519 Publications • 40,898 Citations
  • M. Kris
  • 744 Publications • 61,807 Citations
  • Publications
  • Influence
Erlotinib in previously treated non-small-cell lung cancer.
TLDR
Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects. Expand
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
TLDR
Treatment with pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer side effects compared with docetaxel in the second-line treatment of patients with advanced NSCLC and should be considered a standard treatment option for second-liners when available. Expand
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
TLDR
Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M‐positive advanced non‐small‐cell lung cancer (including those with CNS metastases) in whom disease had progressed during first‐line EGFR‐TKI therapy. Expand
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
TLDR
Treatment with docetaxel is associated with significant prolongation of survival, and at a dose of 75 mg/m(2), the benefits of docetAXel therapy outweigh the risks. Expand
Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study
TLDR
A large, training–testing, multi-site, blinded validation study to characterize the performance of several prognostic models based on gene expression for 442 lung adenocarcinomas, providing the largest available set of microarray data with extensive pathological and clinical annotation for lungAdenocARCinomas. Expand
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
TLDR
The primary endpoint was overall survival (OS) and an exploratory analysis, OS was improved for patients who underwent lobectomy, but not pneumonectomy, versus chemotherapy plus radiotherapy, compared with standard concurrent chemotherapy and definitive radiotherapy without resection. Expand
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
TLDR
Non-inferior survival of gefitinib compared with docetaxel is established, suggesting that gef itinib is a valid treatment for pretreated patients with advanced non-small-cell lung cancer. Expand
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
TLDR
Postoperative cisplatin-based chemotherapy significantly improves survival in patients with non-small-cell lung cancer (NSCLC). Expand
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
TLDR
Among patients with non-small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit. Expand
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.
TLDR
Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer. Expand
...
1
2
3
4
5
...